Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis

Table 3 Regression modelling: Multivariate regression

Characteristic	95%CI	P value
Male gender	-4.2, 23	0.2
Age (years)	-0.38, 0.55	0.7
Treatment with rifaximin-α	0.95, 17	0.029
Aetiology: Alcohol	-3.7, 13	0.3
Hepatocellular carcinoma	-8.7, 8.2	> 0.9
MELD score	-1.0, 0.78	0.8
Baseline height (cm)	-2.5, 2.2	> 0.9
Baseline weight (kg)	-2.2, 2.6	0.9
Baseline BMI (kg/sq m)	-7.0, 7.4	> 0.9
Testosterone therapy during follow up	-1.6, 29	0.078

MELD: Model of end-stage liver disease; BMI: Body mass index.